Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA). This Phase 2 pilot study is a randomized, double-blind ...

Related Keywords

Pratteln ,Switzerland General ,Switzerland ,United States ,United Kingdom ,France ,America ,Swiss ,Acta Myol ,Shabir Hasham ,Eric Hoffman ,Paula Clemens ,Reveragen Biopharma ,Reveragen Biopharma Inc ,Life Science Alliance ,Santhera Pharmaceuticals ,University Of Pittsburgh School Medicine ,Drug Administration ,Head Global Medical Affairs ,Chiesi Group ,Chief Medical Officer ,Pittsburgh School ,Study Chair ,Orphan Drug ,Fast Track ,Rare Pediatric Disease ,Promising Innovative Medicine ,Proc Natl Acad Sci United States ,North America ,